Compare MDV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDV | MDXH |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Belgium |
| Employees | 12 | N/A |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.4M | 183.4M |
| IPO Year | N/A | 2021 |
| Metric | MDV | MDXH |
|---|---|---|
| Price | $14.70 | $3.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 49.7K | ★ 101.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.71 | $18.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.62 | $1.36 |
| 52 Week High | $17.15 | $5.33 |
| Indicator | MDV | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 47.37 |
| Support Level | $14.11 | $3.05 |
| Resistance Level | $14.96 | $3.78 |
| Average True Range (ATR) | 0.40 | 0.15 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 13.72 | 30.91 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.